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Introduction: The vitamin D binding protein (VDBP, also known as GC-globulin) and
vitamin D deficiency have been associated with chronic obstructive pulmonary disease
(COPD). rs7041 and rs4588 are two single nucleotide polymorphisms of the VDBP gene,
including three common allelic variants (GC1S, GC1F and GC2). Previous studies primarily
assessed the serum levels of vitamin D and VDBP in COPD. However, less is known
regarding the impact of the local release of VDBP on COPD lung function. Thus, we
examined the association of sputum and plasma VDBP with lung function at baseline and
at four years, and examined potential genetic polymorphism interactions.
Methods: The baseline levels of sputum VDBP, plasma VDBP and plasma 25-OH vitamin D,
as well as the GC rs4588 and rs7041 genotypes, were assessed in a 4-year Finnish follow-up
cohort (n = 233) of non-smokers, and smokers with and without COPD. The associations
between the VDBP levels and the longitudinal decline of lung function were further analysed.
Results: High frequencies of the haplotypes in rs7041/rs4588 were homozygous GC1S/1S
(42.5%). Higher sputum VDBP levels in stage I and stage II COPD were observed only in
carriers with GC1S/1S genotype when compared with non-smokers (p = 0.034 and p = 0.002,
respectively). Genotype multivariate regression analysis indicated that the baseline sputum
VDBP and FEV1/FVC ratio at baseline independently predicted FEV1% at follow-up.
Discussion and Conclusion: The baseline sputum VDBP expression was elevated in
smokers with COPD among individuals with the GC1S/1S genotype, and predicted follow-
up airway obstruction. Our results suggest that the GC polymorphism should be considered
when exploring the potential of VDBP as a biomarker for COPD.
Keywords: vitamin D binding protein, VDBP, genotype, COPD, prospective study, sputum
Plain Language Summary
The vitamin D binding protein (VDBP, also known as GC-globulin) and vitamin D deficiency
have been associated with chronic obstructive pulmonary disease (COPD). rs7041 and rs4588
are two single nucleotide polymorphisms of the VDBP gene, including three common allelic
variants (GC1S, GC1F and GC2). Previous studies primarily assessed the serum levels of
vitamin D and VDBP in COPD. However, less is known regarding the impact of the local
release of VDBP on COPD lung function. Thus, we aimed to examine the association of sputum
and plasma VDBP with lung function at baseline and at four years, and the interaction with
genetic polymorphisms in a Finnish four-year follow-up cohort. Sputum VDBP expression in
rs7041 was elevated in smokers with COPD and predicted with follow-up airway obstruction in
individuals with the GC1S/1S genotype. This suggests that GC polymorphism should be
considered when the potential of VDBP as a biomarker for COPD is further evaluated.
Correspondence: Jing Gao
Heart and Lung Centre, Department of
Pulmonary Medicine, University of




International Journal of Chronic Obstructive Pulmonary Disease Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com International Journal of Chronic Obstructive Pulmonary Disease 2020:15 1049–1059 1049
http://doi.org/10.2147/COPD.S234464
DovePress © 2020 Gao et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For

















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
leading causes of morbidity and mortality worldwide,1,2 and
genetic susceptibility also plays a role in airway disease.3
Although cigarette smoking is the main environmental risk
factor for COPD, it is still unknown why airway obstruction is
not present in all smokers. Exposure to sunlight and dietary
intake are the main means by which to acquire vitamin D in
humans.4 Acquired vitamin D results in 25-hydroxyl vitamin
D (25-OH vitamin D),5,6 and approximately 85% of circulat-
ing 25-OH vitamin D is tightly bound to the vitamin D binding
protein (VDBP).4 VDBP, known as a group-specific compo-
nent (GC) globulin, ~58 kDa in size,7 is best known as the
main carrier of vitamin D metabolites, which could affect
COPD through various overlapping mechanisms,8 VDBP car-
ries immunomodulatory functions relevant in the lung and the
majority of evidence relates to COPD.8 VDBP relates to
macrophage activation and neutrophil chemotaxis, and
enhances the chemotactic activity of the complement peptide
C5a and its breakdown product C5a des-Arg.8–10 Furthermore,
higher sputum VDBP levels correlated with an increased
macrophage activation in patients with alpha-1-antitrypsin
deficiency.11 Previous studies primarily assessed the serum
levels of VDBP in COPD, whereas less is known regarding
the impact of the local release of VDBP on COPD lung
function. In the Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints (ECLIPSE) study,
serum VDBP neither predicted the progression of COPD,
such as changes in lung function and exacerbations,12 nor
correlated with emphysema or forced expiratory volume in 1
s (FEV1).13 Yet, higher serum levels of VDBPwere associated
with a lower FEV1 in alpha-1-antitrypsin deficient patients in
a cross-sectional study.11 Sputum VDBP levels were signifi-
cantly elevated in vitamin D deficient patients with bronch-
iectasis and also associated with increased airway
inflammation.14 In our previous proteomic screening study,
we identified elevated VDBP in the sputum of smokers with
COPD compared to non-smokers and smokers without
COPD.15–17
Single nucleotide polymorphisms (SNPs) in the VDBP
encoding genetic variations in the GC have been asso-
ciated with FEV118 and levels of 25-OH vitamin D19,20
in genome-wide association studies. In candidate gene
approaches, two common SNPs in the GC gene, rs7041
[T->G, Asp (432) Glu] and rs4588[C->A, Thr (436) Lys],
have been associated with a risk for COPD21 and 25-OH
vitamin D levels.22–24 Combinations of these GC SNPs
result in three common variants: GC1F, GC1S and GC2,
each of which differ in their amino acid sequences at
positions 432 and 436.8,25 The alleles included (a) GC1F
(rs7041-T/rs4588-C); (b) GC1S (rs7041-G/rs4588-C); and
(c) GC2 (rs7041-T/rs4588-A), inclu1F, 1S/1F, 1S/1S, 2/2)
or heterozygous (1F/2, 1F/1S, 1S/2) genotype.26–28 In
recent meta-analyses, the GC1S and GC1F variants asso-
ciated with COPD in Asians, although results among
Caucasians remain inconsistent.19,21,29 GC1F and GC1S
are hypothesised to deliver 25-OH vitamin D to target
tissues more efficiently than GC2.30 Furthermore, GC2 is
less able to activate macrophages31 resulting in reduced
macrophage functioning in GC2 carriers when compared
to carriers of GC1F and GC1S. This could result in
reduced pulmonary inflammation in GC2 carriers and
may in part explain results from recent meta-analyses
showing that the GC2 variant protects against COPD in
Asian populations.21,32 Thus, a comprehensive investiga-
tion of these SNPs’ stratification in sputum and plasma
VDBP expression in a longitudinal COPD study is
warranted.
Taken together, vitamin D and VDBP are involved in
a complex metabolic pathway that could affect COPD through
different overlapping mechanisms. The GC gene variants may
affect COPD by altering the 25-OH vitamin D levels and by
modulating the direct effects of VDBP on pulmonary inflam-
mation. We propose that sputum VDBP might represent
a more specific biomarker of local inflammation and lung
damage in COPD than circulating VDBP. We hypothesised
that the local release of VDBP independent of vitaminD levels
influences longitudinal outcomes in COPD. Thus, our study
aimed to examine the association of sputum and plasma
VDBP with smoking and the trajectory of lung functioning
over a four-year follow-up period in smokers with and without
COPD, including the effects of a GC polymorphism.
Methods
Participants and Samples
Our cohort of 233 subjects (58.4% men), which at baseline
consisted of healthy non-smokers (NS, n = 32), healthy smo-
kers without COPD (HS, n = 157), smokers with COPD stage
I (COPD st I, n = 21) and stage II and III (COPD st II+, n = 23),
forms a part of a longitudinal study conducted in Finland.33 All
participants reported that they felt healthy, took nomedications
andwere not affected by any other exposures or comorbidities.
Upon enrolment, no samples or spirometry were collected.
Two years following enrolment, we assessed the smoking
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status, and baseline spirometry, plasma and sputum samples
were collected. The exclusion criteria consisted of the presence
of lung disease or another disease; the regular use of
a medication; risk factors for lung disease such as allergies,
infections and exposures; a history of asthma or any previous
lung infection including pneumonia or bronchiectasis;
a malignancy; and a viral infection during the previous two
months.34,35 Thus, none of the participants had comorbidities
or took medications nor were affected by any other exposures
at the time of enrolment. Spirometrywas conducted at baseline
and at follow-up in all subjects. All smokers in the study had
a cigarette smoking history of ≥10 years. A COPD diagnosis
was assessed at baseline according to the 2007 GOLD criteria.
The workflow appears in Figure 1.
Peripheral whole venous blood was collected in EDTA
tubes and plasma was prepared by centrifugation and stored
at −80°C until analysis. Sputum samples were processed
using the sputum plug method as described elsewhere.36,37
Only representative sputum samples containing less than
70% squamous epithelial cells were included for analysis.
Proteomics, Western Blot and ELISA
We described the detection and identification of VDBP
(n = 21) using two-dimensional difference gel electrophoresis
(2D-DIGE) andmass spectrometry (MS) in purified sputum (5
μg; n = 21) in detail in our earlier study.15 Immunoblotting of
the sputum samples (n = 21) relied onWestern blot (n = 14) as
previously described.38 VDBP levels and 25-OH vitamin
D levels (n = 233) were analysed using the Human Vitamin
DBP Quantikine ELISA kit (R&D Systems) according to the
manufacturer’s instructions and the 25-OH vitamin D ELISA
kit (Biovendor) according to the manufacturer’s instructions.
The limits of detection in VDBP and 25-OH vitamin D were
3.74 ng/mL and 1.9 ng/mL, respectively.
Genotyping of rs7041 and rs4588
We investigated the distribution of two common GC
genotypes (rs4588 and rs7041) among the study groups
as well as their effect on VDBP levels. DNA was
extracted from whole blood using the FlexiGene DNA
kit (Qiagen) according to the manufacturer’s instruc-
tions. Genotyping of GC rs7041 and rs4588 was per-
formed using Sanger sequencing. Amplification of the
samples was performed in a 20 µL volume containing
~20 ng of sample DNA, 0.25 µM of each primer
(VDBP_F primer TCATTGCAAAGACAGCCAAG and
VDBP_R TCTCGAAGAGGCATGTTTCA) and the
Phusion High-Fidelity PCR Master Mix (Thermo
Figure 1 The workflow of the study design.
Abbreviations: VDBP, vitamin D binding protein; GC, VDBP also known as group-specific component-globulin; GC1F, rs7041-T/rs4588-C; GC1S, rs7041-G/rs4588-C;
GC2, rs7041-T/rs4588-A; COPD, chronic obstructive pulmonary disease; Smokers, smokers without COPD.
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Scientific Inc). Initial denaturation took place at 98°C for
30 s, followed by 30 cycles at 98°C for 10 s, at 63°C for
30 s and at 72°C for 15 s. The final extension took place
at 72°C for 10 min, followed by holding at 10°C. DNA
template purification was performed with resin and
Performa DTR v3 filter plates (EdgeBio). The BigDye
v.3.1 chemistry (Applied Biosystems) sequencing reac-
tion was performed for purified DNA templates (2 µL)
with VDBP_F and VDBP_R primers at 96°C for 60 s; 29
cycles took place at 96°C for 10 s, at 60°C for 10 s, at
60°C for 4 min followed by holding at 10°C in a volume
of 10 µL. The sequencing reaction purification was per-
formed with Performa DTR v3 filter plates (EdgeBio)
and electrophoresis was carried out using the ABI3730xl
DNA Analyzer. Base calling was performed with the
Sequencing Analysis software version 5.2 (Applied
Biosystems), while the SNP analysis for rs7041 and
rs4588 was performed using the variant reporter software
version 1.0 (Applied Biosystems).
Statistical Analysis
The distribution of the basic subject characteristics was calcu-
lated using the means and standard deviations (SD) or percen-
tages, as well as with the medians and interquartile ranges
(IQRs). Comparisons between continuous variables among
the study groups were calculated using the Kruskal–Wallis
test, followed by the Mann–Whitney U-test, whereas the χ2
test was used for categorical variables. The Spearman’s rank
correlation was used to evaluate the association between bio-
marker concentrations with other variables. To obtain an inde-
pendent predictor for follow-up FEV1%, we performed
multivariate regression analyses. All statistical analyses were
performed using IBM’s SPSS Statistics version 21 (SPSS,
Chicago, IL, USA) and GraphPad Prism version 6.00
(GraphPad Software, San Diego, CA, USA). We considered
p < 0.05 as statistically significant.
Ethics Statement
All the samples were analysed anonymously. This study
was approved by the Ethics Committee of the Lapland
Central Hospital (4 June 2003 and 31 October 2006), and
all participants provided their written informed consent.
Results
Participant Characteristics
The baseline and follow-up characteristics of the participants
in each of the study groups appear in Table 1. The mean
value of age was 53.9 years at baseline, and COPD stage II+
patients were significantly older than participants in the
other groups. The predicted FEV1% was significantly dif-
ferent between all groups at baseline and at follow-up. We
found that 66.5% of participants at baseline were current
smokers, and the 37.8% participants had a cough.
Table 2 summarises the frequencies of the GC rs4588
and GC rs7041 genotypes in the different study groups.
The occurrence of the rs7041 and rs4588 genotypes did
not significantly differ between the COPD and non-COPD
groups (p = 0.216 and p = 0.141, respectively). The fre-
quencies of the haplotypes in rs7041/rs4588 included
homozygous GC1S/1S (42.5%), 1F/1F (2.1%) and 2/2
(2.6%) as well as heterozygous 1F/1S (15.9%), 1F/2
(36.5%) and 1S/2 (0.4%).
Secreted VDBP Isoform 1 Is Elevated in
the Sputum of Smokers with COPD
In our previous proteomic screening study, we observed
higher sputum VDBP levels in smokers with COPD stage
II compared to healthy non-smokers and smokers without
COPD.15 We detected changes in VDBP at two spots with
similar expression profiles indicating similar regulatory
mechanisms. Because different VDBP variants including
three isoforms as well as full-length and secreted proteins
have been described, we characterised the altered VDBP
variant in more detail. The separation of VDBP in the 2D
gel at pI 5.10/53 kDa (spot 1) and pI 5.14/53 kDa (spot 2)
together with a sequence coverage of amino acids (31–363)
obtained through MS for both spots indicated the presence of
isoform 1 (Figure 2A). Since none of the detected peptides
covered the N-terminal signal peptide (amino acids 1~16),
this points to the presence of the secreted isoform 1 in the
sputum (Figure 2B). This was further confirmed in immuno-
blotting experiments with sputum samples from healthy non-
smokers and smokers with COPD (Figure 2C).
Sputum VDBP Levels Were Elevated in
Patients with COPD
Wepresent the sputumVDBP levels as themedianswith IQRs.
The sputum VDBP levels were significantly elevated among
smokers without COPD (129.4 [59.0~301.0] ng/mL), with
COPD stage I (120.8 [92.3~305.7] ng/mL), and with COPD
stage II+ (223.2 [97.3~987.0] ng/mL) when compared to the
levels of VDBP in the sputum of healthy non-smokers (48.1
[25.7~150.4] ng/mL; Figure 3A). In addition, the sputum
VDBP levels were elevated among smokers with COPD
Gao et al Dovepress
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stage II+ in comparison to smokerswithout COPD (p = 0.010).
No significant difference emerged between study groups in the
plasma VDBP and 25-OH vitamin D levels (p > 0.05, respec-
tively; Figure 3B and C). The 25-OH vitamin D levels were
generally low in the plasma (n=147).We found that 19 healthy
non-smokers (59.3%), 95 smokers without COPD (59.9%), 16
patients with COPD stage I (76.2%), and 17 patients with
COPD stage II+ (73.9%) had a vitamin D deficiency (plasma
25-OH vitamin D <20 ng/mL). The sputum VDBP levels did
not significantly correlate with the plasma VDBP levels nor
with the 25-OH vitamin D levels in all subjects (p > 0.05).
Sputum VDBP Levels in COPD
Associated with GC1S/1S Genotype
The sputum VDBP levels associated with the GC rs7041 and
GC rs4588 genotypes in different study groups (Figure 4A),
whereas no significant difference emerged between groups
according to the genotypes in the plasma VDBP and 25-OH
vitamin D (data not shown). Participants with the rs7041 GG
genotype exhibited higher levels of sputum VDBP in COPD
stage II+ (355.5 [110.2~973.5] ng/mL) when compared to
healthy non-smokers (38.0 [14.9~98.3] ng/mL; p = 0.002,
Figure 4A). The rs4588 CC genotype showed higher levels
of sputum VDBP in COPD stage II+ (242.9 [96.0~973.5] ng/
mL) when compared to smokers (132.3 [72.8~268.2] ng/mL)
and healthy non-smokers (37.4 [25.7~98.3] ng/mL; p = 0.023
and p < 0.001, Figure 4B). The rs4588 CC genotype showed
higher levels of sputum VDBP in COPD stage I (112.1
[98.7~123.2] ng/mL) than in healthy non-smokers (p =
0.003, Figure 4B).
We also studied different genotype combinations of the
rs7041/rs4588 genotype in homozygous (GC1S/1S, 1F/1F and
Table 1 Clinical Characteristics of Study Subjects at Baseline and at the Four-Year Follow-Up (n=233)
Non-Smokers Smokers COPD St I COPD St II+ P-value
(n = 32) (n = 157) (n = 21) (n = 23)
Baseline
Subjects, n 32 157 21 23
Gender (M/F) 12/20 86/71 18/3 20/3 <0.001#
Age years 54.9 (9.6) 52.1 (9.0) 55.1 (8.3) 62.7 (5.8) <0.001*
BMI 26.2 (3.6) 26.9 (3.8) 26.2 (3.3) 28.3 (4.4) 0.259
Smoking status 0.003*
Former smoker n (%) - 33 (21.0) 1 (4.8) 7 (30.4)
Current smoker n (%) - 124 (79.0) 19 (90.5) 12 (52.2)
Pack-years - 28.4 (14.1) 35.5 (12.7) 43.1 (13.0) <0.001*
Symptom <0.001*
Cough n (%) 4 (12.5) 61 (38.9) 9 (42.9) 14 (60.9)
Sputum n (%) 9 (28.1) 91 (58.0) 9 (42.9) 17 (73.9)
Post-bronchodilator
FVC L 3.8 (0.8) 4.0 (1.0) 4.8 (0.8) 3.6 (0.7) <0.001*
Predicted FVC % 102.3 (12.3) 96.3 (12.1) 104.9 (0.1) 86.6 (11.2) <0.001*
FEV1 L 3.2 (0.6) 3.3 (0.8) 3.2 (0.5) 2.1 (0.5) <0.001*
Predicted FEV1% 106.5 (14.6) 96.5 (12.5) 87.3 (5.2) 63.8 (11.4) <0.001*
FEV1/FVC % 84.5 (5.3) 81.6 (5.4) 67.2 (2.7) 59.8 (7.8) <0.001*
At the 4-year follow-up
Post-bronchodilator
FVC L 3.6 (0.8) 3.8 (0.9) 4.5 (0.8) 3.4 (0.7) <0.001*
Predicted FVC % 100.4 (13.4) 96.2 (11.8) 101.5 (9.3) 85.6 (14.9) <0.001*
FEV1 L 2.9 (0.6) 3.0 (0.8) 2.8 (0.5) 1.8 (0.6) <0.001*
Predicted FEV1% 100.8 (13.9) 90.8 (13.4) 78.7 (7.6) 56.4 (14.8) <0.001*
FEV1/FVC % 81.4 (4.7) 76.6 (7.1) 62.8 (6.5) 53.2 (9.3) <0.001*
Notes: The demographic characteristics are presented as the mean (standard deviation) unless otherwise stated. Differences were analysed using the Kruskal–Wallis
H-test* and the chi-square test#.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; COPD, chronic obstructive pulmonary disease; Smokers: smokers
without COPD; COPD St I, smokers with COPD stage I; COPD St II+, smokers with COPD stage II+.
Dovepress Gao et al



















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
2/2) and heterozygous (1F/1S, 1S/2 and 1F/2) individuals.
Among the studied genotypes in rs7041/rs4588, only GC1S/
1S showed different sputum VDBP levels between the groups
with higher levels in COPD st I (112.1 [103.4~123.2] ng/mL)
and COPD st II+ (355.5 [110.2~973.5.0] ng/mL) individuals
compared to healthy non-smokers (38.0 [14.9~92.3] ng/mL;
p = 0.034 and p = 0.002, respectively; Figure 4C).
Sputum VDBP Levels Associated with
Follow-Up FEV1% Predicted in COPD in
GC1S/1S Genotype
Baseline sputum VDBP levels positively correlated with body
mass index (BMI) and pack years among all participants,
whereas we identified an inverse correlation between BMI
and pack years associated with predicted FEV1% at baseline
and follow-up (p < 0.05, Table 3). In addition, the levels of
plasma VDBP and vitamin D did not significantly correlate
with lung function at baseline and follow-up in all subjects, nor
rs7041 GG (1S), in rs4588 CC (1S) and GC 1S/1S (data not
shown). Sputum VDBP expression with GC1S/1S negatively
associated with the predicted FEV1% at follow-up (n = 99,
r = −0.240, p = 0.017; Figure 5) in the univariate analysis, but
not in GC1F/1S (n = 37, r = −0.065, p = 0.703) and GC1F/2
(n = 85, r =−0.077, p = 0.485).Multivariate regression analysis
indicated that baseline sputumVDBP and the FEV1/FVC ratio
at follow-up independently predicted FEV1% at follow-up in
GC1S/1S genotype after adjusting for age, gender, BMI, smok-
ing, plasma VDBP and vitamin D deficiency (Table 4). In
contrast, those variables did not significantly predict FEV1%
at follow-up in GC1F/1S and GC 1S/2 (Table 4).
Discussion
Here, we found higher sputum VDBP levels in COPD
patients associated with GC1S/1S compared to the levels
among healthy non-smokers. Sputum VDBP emerged as
an independent predictor for future airway obstruction in
participants with the G1S/1S genotype. Plasma VDBP and
25-OH vitamin D levels did not differ between the study
groups, and did not significantly differ between COPD
patients with and without vitamin D deficiency (plasma
25-OH vitamin D < 20 ng/mL). In agreement with pre-
vious findings,11 the sputum VDBP levels did not correlate
with the plasma VDBP levels. These observations suggest
that the elevated sputum VDBP levels in COPD patients
were related to the local release of VDBP independent of
Table 2 Frequencies of the GC rs7041 and the GC rs4588 Genotypes in the Study Cohort
Non-Smokers Smokers COPD St I COPD St II+ Total
(n = 32) (n = 157) (n = 21) (n = 23) (n = 233)
GC rs7041
432Asp/Asp (TT) 5 (15.6) 15 (9.6) 1 (4.8) 2 (8.7) 23 (9.9)
432Asp/Glu (TG) 19 (59.4) 74 (47.1) 10 (47.6) 7 (30.4) 110 (47.2)
432Glu/Glu (GG) 8 (25.0) 68 (43.3) 10 (47.6) 14 (60.9) 100 (42.9)
GC rs4588
436Thr/Thr (CC) 12 (37.5) 98 (62.5) 13 (61.9) 18 (78.3) 141 (60.5)
436Thr/Lys (CA) 19 (59.4) 55 (35.0) 6 (28.6) 5 (21.7) 85 (36.5)
436Lys/Lys (AA) 1 (3.1) 4 (2.5) 2 (9.5) 0 (0) 7 (3.0)
GC rs7041/rs4577
Homozygous
GC1S/GC1S (GG/CC) 8 (25.0) 68 (43.3) 9 (42.9) 14 (60.9) 99 (42.5)
GC1F/GC1F (TT/CC) 1 (3.1) 3 (1.9) 0 (0) 1 (4.3) 5 (2.1)
GC2/GC2 (TT/AA) 1 (3.1) 4 (2.5) 1 (4.8) 0 (0) 6 (2.6)
Heterozygous
GC1F/GC1S (TG/CC) 3 (9.4) 27 (17.2) 4 (19.0) 3 (13.0) 37 (15.9)
GC1F/GC2 (TG/CA) 16 (50.0) 47 (29.9) 6 (28.6) 4 (17.4) 73 (31.3)
GC1F/GC2 (TT/CA) 3 (9.4) 8 (5.1) 0 (0) 1 (4.3) 12 (5.2)
GC1S/GC2 (GG/AA) 0 (0) 0 (0) 1 (4.8) 0 (0) 1 (0.4)
Notes: Data are presented as n (%) unless otherwise stated.
Abbreviations: GC, VDBP also known as group-specific component-globulin; rs7041, T->G, Asp (432) Glu; rs4588, C->A, Thr (436) Lys; GC1F, rs7041-T/rs4588-C; GC1S,
rs7041-G/rs4588-C; GC2, rs7041-T/rs4588-A; COPD, chronic obstructive pulmonary disease; Smokers, smokers without COPD; COPD St I, smokers with COPD stage I;
COPD St II+, smokers with COPD stage II+.
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vitamin D carriage. In contrast, circulating VDBP may be
affected by several confounding factors and may not repre-
sent a specific biomarker for COPD. These findings sug-
gest that the sputum levels of VDBP might serve as
a potential marker for COPD screening and predict
COPD progression. In addition, genetic polymorphisms
may affect the link between VDBP and the pathogenesis
of COPD.
Previous studies identified significant associations
between the sputum VDBP levels and markers of airway
inflammation.14 Sputum VDBP may enhance macrophage
activation11 and neutrophil recruitment,9,10 resulting in
immunomodulatory functions relevant to the lung.8 In
our previous study, altered VDBP was detected in two
spots with similar expression profiles indicating similar
regulatory mechanisms. Here, the sputum VDBP levels
were elevated in patients with COPD stage II+ compared
with the levels in non-smokers and smokers overall and in
the GC1S/1S genotype specifically. VDBP serves as the
primary carrier of vitamin D metabolites, whereas sputum
Figure 2 Secreted VDBP is upregulated in the sputum of smokers with COPD.
Notes: (A) Representative 2D gel of the sputum from a characteristic COPD patient (stage II). Altered protein spots of VDBP indicated by 1 and 2. Histogram
corresponding to the spot numbers indicates the protein levels in non-smokers (NS), smokers (S) and COPD patients (C). (B) A representative mass spectrum (MS) of the
altered VDBP. Peptides marked with grey arrows matched to all three isoforms whereas the black arrows matched only to isoforms 1 and 3. The schematic presentation of
VDBP shows the signal peptide (SP) and the sequence coverage of the spot-specific peptides detected by MS. The N-terminal peptide of the mature VDBP indicated by an
asterisk. (C) Western blot of the sputum from non-smokers (NS, n = 7) and smokers with COPD stage II (COPD, n = 7).
Abbreviations: VDBP, vitamin D binding protein; COPD, chronic obstructive pulmonary disease; NS, non-smokers; S, smokers without COPD; C, COPD; MS, mass
spectrum; SP, signal peptide.
Figure 3 Levels of VDBP and 25-OH vitamin D at baseline for (A) sputum VDBP, (B) plasma VDBP and (C) plasma 25-OH vitamin D.
Abbreviations: VDBP, vitamin D binding protein; COPD, chronic obstructive pulmonary disease; Smokers, smokers without COPD; COPD St I, smokers with COPD stage
I; COPD St II+, smokers with COPD stage II+.
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VDBP did not correlate with plasma 25-OH vitamin
D levels in our study. Notably, high sputum VDBP levels
were associated with pack years at baseline, although
smoking status did not emerge as an independent factor
predicting sputum VDBP when compared with other vari-
ables. Thus, the elevated sputum VDBP levels in COPD
patients may remain unaffected by the mere exposure to
smoking, although the smoking-related disease process is
affected. Furthermore, high sputum VDBP levels
correlated with low predicted FEV1% levels at baseline
and at follow-up in patients with the GC1/1S genotype, but
did not correlate with changes in lung function after four
years at follow-up. This study predominantly included
smokers without COPD and mild to moderate COPD.
Persson et al showed that vitamin D deficiency correlates
with the longitudinal lung function decline in moderate to
very severe COPD.12 Yet, vitamin D deficiency has been
shown to affect lung growth in early life.39 Our results
identified an association between lung function and spu-
tum VDBP, although further investigation is warranted in
order to clarify whether altering lung VDBP associates
with the development or progression of COPD.
In addition, previous results concerning the associa-
tions of circulating VDBP with COPD and lung function
remain contradictory.11–13 Furthermore, the serum VDBP
Figure 4 Sputum levels of VDBP according to the GC rs7041 and rs4588 at baseline for (A) GC rs7041, (B) GC rs74588 and (C) GC1S/1S in rs7041/rs74588.
Abbreviations: VDBP, vitamin D binding protein; GC, VDBP also known as group-specific component-globulin; rs7041, T->G, Asp (432) Glu; rs4588, C->A, Thr (436) Lys;
GC1S, rs7041-G/rs4588-C; COPD, chronic obstructive pulmonary disease; Smokers, smokers without COPD; COPD St I, smokers with COPD stage I; COPD St II+,
smokers with COPD stage II+.
Table 3 Correlation Between Sputum VDBP and Clinical










Age 0.121 −0.229 0.051
BMI 0.164 0.030 0.251*
Gender 0.077 −0.127 0.181
Pack years 0.182 −0.028 0.260*
Predicted FVC % −0.316** −0.097 0.054
Predicted FEV1% −0.257* −0.042 −0.052
FEV1/FVC % 0.004 −0.036 −0.170




Vitamin D deficiency 0.011 −0.304 −0.200
Follow-up
Predicted FVC % −0.219* −0.005 0.068
Predicted FEV1% −0.240* −0.065 −0.077
FEV1/FVC % −0.064 −0.158 −0.200
Notes: Data are analysed by Spearman correlation. *p<0.05 and **p<0.001.
Abbreviations: VDBP, vitamin D binding protein; GC: VDBP also known as group-
specific component-globulin; GC1F, rs7041-T/rs4588-C; GC1S, rs7041-G/rs4588-C;
GC2, rs7041-T/rs4588-A; BMI, body mass index; FEV1, forced expiratory volume in 1
s; FVC, forced vital capacity.
Figure 5 Correlation between sputum VDBP and predicted FEV1% at follow-up
based on GC1S/1S genotype.
Abbreviations: VDBP, vitamin D binding protein; GC, VDBP also known as group-
specific component-globulin; GC1S, rs7041-G/rs4588-C; FEV1: forced expiratory
volume in 1 s; Log10, the logarithm base 10.
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and vitamin D levels were inversely correlated,12–14
whereas another study found no correlation.11 The rs7041
SNP gene explained 71% to 75% of the measured varia-
tion in plasma VDBP,40 whereas we found no significant
difference in the plasma VDBP rs7041 GG (1S) genotype
among the groups in our study. Thus, circulating VDBP
may be affected by several confounding factors and may
not represent a specific biomarker for COPD.
The strength of this study lies in our systematic investiga-
tion of VDBP gene polymorphism in a well-characterised
follow-up cohort using several types of samples. The fre-
quencies of the different rs4588 and rs7041 genotypes agreed
well with those previously detected in a Finnish population
stored in the Sequencing Initiative Suomi database (http://
www.sisuproject.fi/). Our study also carries several limita-
tions. First, the VDBP immunoassay may have been affected
by polymorphisms with a lower VDBP detection in the
GC1F variant.41 However, GC1F was rare in our cohort, in
which only five individuals were homozygotes for this geno-
type. In addition, we must note that this study is insufficiently
powered to allow for an examination of the genetic associa-
tions of GC variants with COPD. Second, the number of
participants in the COPD groups was relatively small.
A larger number of COPD samples and a validation cohort
would be necessary to further confirm the association
between the sputum VDBP and follow-up airway obstruc-
tion. Third, our sample was gender imbalanced, given that
the COPD group included only six women participants.
Thus, we did not use gender further in our correlation analy-
sis. Fourth, we found no significant correlation between the
sputum VDBP and the longitudinal decline of lung function
in a univariate analysis. We attribute this result to the small
change in the absolute lung function value. Therefore, further
investigation with follow-up period longer than 4 years in
patients with various levels of severity would be needed to
clarify this point.
In conclusion, our results show that the sputum VDBP
expression levels are elevated in smokers with COPD and
predict with follow-up airway obstruction in individuals
with the GC1S/1S genotype. Gene polymorphism should
be considered when the potential of VDBP as a biomarker
for COPD is further evaluated.
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